Examining treatment outcomes with erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon EGFR mutations

Journal of Thoracic Oncology

Volumn 11, Issue 4, 2016, Pages 545-555

  Klughammer, Barbara ^a   Brugger, Wolfram ^b   Cappuzzo, Federico ^c   Ciuleanu, Tudor ^d,e   Mok, Tony ^f   Reck, Martin ^g,h   Tan, Eng Huat ^h   Delmar, Paul ^a   Klingelschmitt, Gaëlle ^a   Yin, Anny Yue ^a   Spleiss, Olivia ^a   Wu, Lin ^a   Shames, David S ⁱ  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

^c ISTITUTO TOSCANO TUMORI   (Italy)

^d Prof Dr Ion Chiricu Institute of Oncology   (Italy)

^e IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^g Mitglied im DZL   (Germany)

^h DIVISION OF MEDICAL ONCOLOGY   (Singapore)

ⁱ GENENTECH INC   (United States)

Author keywords

EGFR mutations; Erlotinib; NSCLC; Rare; Uncommon

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; PLACEBO; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; DRUG EFFICACY; DRUG SENSITIVITY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; GENE; GENE MUTATION; HUMAN; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; ADULT; AGED; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); ENZYMOLOGY; FEMALE; GENETICS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84962919806     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2015.12.107     Document Type: Article

References (37)

1. Shepherd F, Rodrigues Pereira J, Ciuleanu T, et al. Erlo-tinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
2. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11:521-529.
3. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor mutations in lung cancer. N Engl J Med. 2009;361:958-967.
4. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735-742.
5. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-246.
6. De Pas T, Toffalorio F, Manzotti M, et al. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small-cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol. 2011;6:1895-1901.
7. Arrieta O, Cardona A, Corrales L, et al. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small-cell lung cancer. Lung Cancer. 2015;87:169-175.
8. Chiu CH, Yang CT, Shih JY, et al. Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations. J Thorac Oncol. 2015;10:793-799.
9. Baek J, Sun J, Min Y, et al. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea. Lung Cancer. 2015;87:148-154.
10. Yang J, Sequist L, Geater S, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3 and LUX-Lung 6. Lancet Oncol. 2015;16:830-838.
11. Tan E-H, Ramlau R, Pluzanska A, et al. A multicentre phase II gene expression profiling study of putative relationships between tumor biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann Oncol. 2010;21:217-222.
12. Reck M, van Zandwijk N, Gridelli C, et al. Erlotinib in advanced non-small-cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol. 2010;5: 1616-1622.
13. Schneider C-P, Heigener D, Schott-von-Römer K, et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the TRUST study. J Thorac Oncol. 2008;3:1446-1453.
14. Pirker R, Su W, Rooneem R, et al. Clinical outcomes with erlotinib in relation to biomarker status: analyses from the open-label TRUST study in advanced non-small-cell lung cancer (NSCLC) [abstract]. Ann Oncol. 2008;19(suppl 8):viii100.
15. Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13:300 308.
16. Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2011;29:4113-4120.
17. Wu YL, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FAS-TACT-2): a randomised, double-blind trial. Lancet Oncol. 2013;14:777 786.
18. Herbst R, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011;377:1846-1854.
19. Johnson B, Kabbinavar F, Fehrenbacher L, et al. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2013;31:3926-3934.
20. Massarelli E, Johnson F, Erickson H, et al. Uncommon epidermal growth factor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer. 2013;80:235 241.
21. Han S, Kim T, Hwang P, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefiti-nib. J Clin Oncol. 2005;23:2493-2501.
22. Wu J-Y, Yu C-J, Chang Y-C, et al. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small-cell lung cancer. Clin Cancer Res. 2011;17:3812 3821.
23. Chou T, Chiu C, Li L, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res. 2005;11:3750 3757.
24. Peng L, Song Z, Jiao S. Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation. Onco Targets Ther. 2015;8:905-910.
25. Ning J, Wu Q, Liu Z, et al. Mapping inhibitor response to the in-frame deletions, insertions and duplications of epidermal growth factor receptor (EGFR) in non-small cell lung cancer. J Recept Signal Transduct Res. 2015;22:1-8.
26. Agbarya A, Melamed-Frank M, Kaidar-Person, et al. Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib. SpringerPlus. 2014;3:507.
27. Chan A, Tong J, Lo SH, et al. An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment. J Thorac Oncol. 2013;8:e107-e108.
28. Gazdar A. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28: 24-31.
29. Masago K, Fujita S, Irisa K, et al. Good clinical response to gefitinib in a non-small-cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I). Jpn J Clin Oncol. 2010;40:1105-1109.
30. Pallan L, Taniere P, Koh P. Rare EGFR exon 20 S768I mutation predicts resistance to targeted therapy: a report of two cases. J Thorac Oncol. 2014;9:75.
31. Kancha R, von Bubnoff N, Peschel C, et al. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res. 2009;15:460-467.
32. Lund-Iversen M, Kleinberg L, Fjellbirkeland L, et al. Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations. J Thorac Oncol. 2012;7:1471-1473.
33. Naidoo J, Sima C, Rodriguez K, et al. Epidermal growth factor receptor exon 20 insertions in advanced lung ad-enocarcinomas: clinical outcomes and response to erlo-tinib. Cancer. 2015;121:3212-3220.
34. Oxnard GR, Lo P, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8: 179-184.
35. Wantanbe S, Minegishi Y, Yoshizawa H, et al. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol. 2014;9:189-194.
36. Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarci-noma. J Clin Invest. 2014;124:1582-1586.
37. My Cancer Genome. DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT). http://www.mycancergenome.org/about/direct. Accessed March 13, 2015.